Top

Published in:

01-03-2015 | Breast Cancer (B Overmoyer, Section Editor)

Metaplastic Breast Cancer: Clinical Overview and Molecular Aberrations for Potential Targeted Therapy

Authors: Sausan Abouharb, Stacy Moulder

Published in: Current Oncology Reports | Issue 3/2015

Abstract

Metaplastic breast cancer is a rare subtype of invasive mammary carcinoma, with an aggressive behavior and usually poor outcome. Responses to systemic chemotherapy are suboptimal compared to patients with standard invasive ductal carcinoma. Limited data are available in regards to best treatment modalities, including chemotherapy. This review gives an overview of metaplastic breast cancer and its clinical and pathologic characteristics, in addition to treatment strategies, clinical trials, and future directions.

Gogas J, Kouskos E, Markopoulos C, Mantas D, Antonopoulou Z, Kontzoglou K, et al. Carcinosarcoma of the breast: report of two cases. Eur J Gynaecol Oncol. 2003;24(1):93–5.PubMed

Aritas Y, Bedirli A, Karahan OI, Okten T, Sakrak O, Ince O. Carcinosarcoma of the breast: clinicopathologic and radiologic findings in an unusual case. Breast J. 2003;9(4):323–4. doi:10.1046/j.1524-4741.2003.09416.x.CrossRefPubMed

Tse GM, Tan PH, Putti TC, Lui PC, Chaiwun B, Law BK. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol. 2006;59(10):1079–83. doi:10.1136/jcp.2005.030536.CrossRefPubMedCentralPubMed

Wada H, Enomoto T, Tsujimoto M, Nomura T, Murata Y, Shroyer KR. Carcinosarcoma of the breast: molecular-biological study for analysis of histogenesis. Hum Pathol. 1998;29(11):1324–8.CrossRefPubMed

Foschini MP, Dina RE, Eusebi V. Sarcomatoid neoplasms of the breast: proposed definitions for biphasic and monophasic sarcomatoid mammary carcinomas. Semin Diagn Pathol. 1993;10(2):128–36.PubMed

Bocker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol. 2002;86:116–9.PubMed

Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat. 2011;126(2):471–8. doi:10.1007/s10549-011-1359-8.CrossRefPubMed

Okada N, Hasebe T, Iwasaki M, Tamura N, Akashi-Tanaka S, Hojo T, et al. Metaplastic carcinoma of the breast. Hum Pathol. 2010;41(7):960–70. doi:10.1016/j.humpath.2009.11.013.CrossRefPubMed

Stanley MW, Tani EM, Skoog L. Metaplastic carcinoma of the breast: fine-needle aspiration cytology of seven cases. Diagn Cytopathol. 1989;5(1):22–8.CrossRefPubMed

10.

Gupta RK. Cytodiagnostic patterns of metaplastic breast carcinoma in aspiration samples: a study of 14 cases. Diagn Cytopathol. 1999;20(1):10–2. doi:10.1002/(SICI)1097-0339(199901)20:1<10::AID-DC3>3.0.CO;2-5.CrossRefPubMed

11.

Patterson SK, Tworek JA, Roubidoux MA, Helvie MA, Oberman HA. Metaplastic carcinoma of the breast: mammographic appearance with pathologic correlation. AJR Am J Roentgenol. 1997;169(3):709–12. doi:10.2214/ajr.169.3.9275883.CrossRefPubMed

12.•

Leddy R, Irshad A, Rumboldt T, Cluver A, Campbell A, Ackerman S. Review of metaplastic carcinoma of the breast: imaging findings and pathologic features. J Clin Imaging Sci. 2012;2:21. doi:10.4103/2156-7514.95435. Pathologic and imaging findings that physicians should be aware of to recognize metaplastic breast cancer.CrossRefPubMedCentralPubMed

13.•

Choi BB, Shu KS. Metaplastic carcinoma of the breast: multimodality imaging and histopathologic assessment. Acta Radiol. 2012;53(1):5–11. doi:10.1258/ar.2011.110341. Imaging and pathologic factors to be considered in the diagnosis of metaplastic breast cancer that should alert oncologists.CrossRefPubMed

14.

Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166–73. doi:10.1245/s10434-006-9124-7.CrossRefPubMed

15.••

Song Y, Liu X, Zhang G, Song H, Ren Y, He X, et al. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol. 2013;11:129. doi:10.1186/1477-7819-11-129. Comparison between clinicopathological features and outcomes of metaplastic breast carcinoma and invasive ductal carcinoma, showing a poorer outcome in metaplastic breast carcinoma.CrossRefPubMedCentralPubMed

16.

Lai HW, Tseng LM, Chang TW, Kuo YL, Hsieh CM, Chen ST, et al. The prognostic significance of metaplastic carcinoma of the breast (MCB)—a case controlled comparison study with infiltrating ductal carcinoma. Breast. 2013;22(5):968–73. doi:10.1016/j.breast.2013.05.010.CrossRefPubMed

17.

Kuo SH, Chen CL, Huang CS, Cheng AL. Metaplastic carcinoma of the breast: analysis of eight Asian patients with special emphasis on two unusual cases presenting with inflammatory-type breast cancer. Anticancer Res. 2000;20(3B):2219–22.PubMed

18.

Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116–24. doi:10.1158/0008-5472.CAN-08-3441.CrossRefPubMedCentralPubMed

19.

Santiago Perez JT, Perez Vazquez MR, Rivera Valdespino Ade L, Gil Valdes D. Carcinosarcoma of the breast: a tumour with controversial histogenesis. Clin Transl Oncol. 2005;7(6):255–7.CrossRefPubMed

20.

Teixeira MR, Qvist H, Bohler PJ, Pandis N, Heim S. Cytogenetic analysis shows that carcinosarcomas of the breast are of monoclonal origin. Genes, Chromosomes Cancer. 1998;22(2):145–51.CrossRefPubMed

21.

Osako T, Horii R, Ogiya A, Iijima K, Iwase T, Akiyama F. Histogenesis of metaplastic breast carcinoma and axillary nodal metastases. Pathol Int. 2009;59(2):116–20. doi:10.1111/j.1440-1827.2008.02339.x.CrossRefPubMed

22.••

Schwartz TL, Mogal H, Papageorgiou C, Veerapong J, Hsueh EC. Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol. 2013;2(1):31. doi:10.1186/2162-3619-2-31. A great updated overview of Metaplastic Breast Cancer.CrossRefPubMedCentralPubMed

23.

Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol. 1989;20(7):628–35.CrossRefPubMed

24.

Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer. 1990;65(2):272–6.CrossRefPubMed

25.

Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol. 1989;20(8):732–40.CrossRefPubMed

26.

Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol. 1990;21(11):1142–50.CrossRefPubMed

27.

Oberman HA. Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol. 1987;11(12):918–29.CrossRefPubMed

28.

Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer. 1999;85(10):2170–82.CrossRefPubMed

29.

Park HS, Park S, Kim JH, Lee JH, Choi SY, Park BW, et al. Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast. Yonsei Med J. 2010;51(6):864–9. doi:10.3349/ymj.2010.51.6.864.CrossRefPubMedCentralPubMed

30.

Sanguinetti A, Lucchini R, Santoprete S, Farabi R, Fioriti L, Bistoni G et al. Metaplastic carcinoma of the breast treatment, results and prognostic factors based on international literature. Ann Ital Chir. 2013; 84.

31.

Esbah O, Turkoz FP, Turker I, Durnali A, Ekinci AS, Bal O, et al. Metaplastic breast carcinoma: case series and review of the literature. Asian Pac J Cancer Prev. 2012;13(9):4645–9.CrossRefPubMed

32.

Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413–9.CrossRefPubMed

33.

Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17(4):605–13. doi:10.1093/annonc/mdl006.CrossRefPubMed

34.

Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer. 1989;64(7):1490–9.CrossRefPubMed

35.

Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010;120(3):627–37. doi:10.1007/s10549-010-0780-8.CrossRefPubMed

36.

Lester TR, Hunt KK, Nayeemuddin KM, Bassett Jr RL, Gonzalez-Angulo AM, Feig BW, et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat. 2012;131(1):41–8. doi:10.1007/s10549-011-1393-6.CrossRefPubMed

37.

Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101(3):349–53. doi:10.1007/s10549-006-9301-1.CrossRefPubMed

38.

Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: clinical significance. Am J Surg. 2006;191(5):657–64. doi:10.1016/j.amjsurg.2006.01.038.CrossRefPubMed

39.

Al Sayed AD, El Weshi AN, Tulbah AM, Rahal MM, Ezzat AA. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol. 2006;45(2):188–95. doi:10.1080/02841860500513235.CrossRefPubMed

40.

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32. doi:10.1056/NEJMoa020989.CrossRefPubMed

41.

Jacobson JA, Danforth DN, Cowan KH, D’Angelo T, Steinberg SM, Pierce L, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. New England J Med. 1995;332(14):907–11. doi:10.1056/NEJM199504063321402.CrossRef

42.•

Hu Q, Chen WX, Zhong SL, Li J, Luo Z, Tang JH, et al. Current progress in the treatment of metaplastic breast carcinoma. Asian Pac J Cancer Prev. 2013;14(11):6221–5. Review of current multimodality treatment recommendations of metaplastic breast cancer.CrossRefPubMed

43.

Chao TC, Wang CS, Chen SC, Chen MF. Metaplastic carcinomas of the breast. J Surg Oncol. 1999;71(4):220–5.CrossRefPubMed

44.

Dave G, Cosmatos H, Do T, Lodin K, Varshney D. Metaplastic carcinoma of the breast: a retrospective review. Int J Radiat Oncol Biol Phys. 2006;64(3):771–5. doi:10.1016/j.ijrobp.2005.08.024.CrossRefPubMed

45.

Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol. 2011;18(1):94–103. doi:10.1245/s10434-010-1198-6.CrossRefPubMedCentralPubMed

46.

Gultekin M, Eren G, Babacan T, Yildiz F, Altundag K, Guler N, et al. Metaplastic breast carcinoma: a heterogeneous disease. Asian Pac J Cancer Prev. 2014;15(6):2851–6.CrossRefPubMed

47.••

Nowara E, Drosik A, Samborska-Plewicka M, Nowara EM, Stanek-Widera A. Metaplastic breast carcinomas - analysis of prognostic factors in a case series. Contemp Oncol. 2014;18(2):116–9. doi:10.5114/wo.2014.41392. Single institution case series with review of outcomes, treatment modalities, and pathologic findings.

48.

Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009;117(2):273–80. doi:10.1007/s10549-008-0197-9.CrossRefPubMed

49.

Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF, Kuo WH, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007;26(57):7859–71. doi:10.1038/sj.onc.1210593.CrossRefPubMed

50.

Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther. 2004;3(11):1058–9. doi:10.4161/cbt.3.11.1302.CrossRefPubMed

51.

Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V, et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell. 2004;6(6):625–30. doi:10.1016/j.ccr.2004.09.033.CrossRefPubMed

52.

Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010;107(35):15449–54. doi:10.1073/pnas.1004900107.CrossRefPubMedCentralPubMed

53.

Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76. doi:10.1186/gb-2007-8-5-r76.CrossRefPubMedCentralPubMed

54.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12(5):R68. doi: 10.1186/bcr2635.

55.

Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C et al. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 29(19):e572-5. doi: 10.1200/JCO.2010.34.0604.

Title: Metaplastic Breast Cancer: Clinical Overview and Molecular Aberrations for Potential Targeted Therapy
Authors: Sausan Abouharb
Stacy Moulder
Publication date: 01-03-2015
Publisher: Springer US
Published in: Current Oncology Reports / Issue 3/2015
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-014-0431-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Pediatric Brainstem Gliomas: New Understanding Leads to Potential New Treatments for Two Very Different Tumors

The Role of Transoral Robotic Surgery in the Management of Oropharyngeal Squamous Cell Carcinoma: a Current Review

The Neoadjuvant Treatment of Rectal Cancer: A Review

Long-Term Experience with (Laterally) Extended Endopelvic Resection (LEER) in Relapsed Pelvic Malignancies

Surgical Salvage of Recurrent Nasopharyngeal Carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer